



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ivan PETYAEV

Atty. Ref.: 620-433

Serial No. 10/574,852

Group: 1623

Filed: April 6, 2006

Examiner: Peselev

For: METHOD AND MEANS FOR MODULATING LIPID
METABOLISM

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 11, 2007

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

09/12/2007 JADD01 00000059 10574852

02 FC:1806

180.00 0P

1248310

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified non-U.S. patent document. A statement of the relevance of the listed "Other Documents" can be found in the International Search Report considered by the Examiner on May 7, 2007 and of record.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information


Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

620-433

APPLICANT

Ivan PETYAEV

FILING DATE

April 6, 2006

SERIAL NO.

10/574,852

GROUP

1623

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|---------|---------|-------|----------|-------------------------------|
| | 2003-0166029 | 9-2003 | Petynev | | | |
| | 2003-0190315 | 10-2003 | Petynev | | | |
| | 2003-0194746 | 10-2003 | Petynev | | | |
| | 7148028 | 12-2006 | Petynev | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|----------|------|---------|-------|----------|-----------------------|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | STEER et al., "Aspirin protects low density lipoprotein from oxidative modification", Heart, Vol. 77, No. 4, 1997, Pgs. 333-337 |
| | SOYBIR et al., "The effects of desferrioxamin and vitamin E as supplements to antibiotics in the treatment of peritonitis in rats", Journal of the Royal College of Surgeons of Edinburgh, Oct. 2002, Vol. 47, No. 5, October 2002, Pgs. 700-704 |
| | POIMIROO et al., "Therapeutic study in dental practice of an antibiotic, antihistamine, and salicylic drug combination", L'Information Dentaire, 1 May 2060, Pgs. 1814-1817 |
| | GURFINKEL et al., "Emerging role of antibiotics in atherosclerosis", American Heart Journal, Vol. 138, No. 5, Part 2, November 1999, Pgs. S537-S538 |
| | |
| | |
| | |

| | |
|-----------|-----------------|
| *Examiner | Date Considered |
|-----------|-----------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)